Ashley Gallagher, Associate Editor

The findings also indicate that that treatment may have protective CV and limb benefits for those with kidney failure and concomitant peripheral artery disease.

Because there is no vaccine for the disease, preventive strategies are needed, investigators from Copenhagen University Hospital in Denmark say.

New TROPiCS-02 data for Gilead treatment demonstrates progression-free survival benefit, regardless of HER2 status.

Patients should discuss efficacy and potential drug interactions with clinicians before use, study authors indicate.

University of California Irvine investigators spotlight links and propose further systematic examination into the molecular underpinnings.

Findings have implications for patients who take supplementary folate to prevent complications of other pharmacological therapies.

The agency’s decision data for the investigational factor VIII therapy from Sanofi and Soba is set for February 28, 2023.

One-third of participants who have used prescriptions think that mail-order pharmacies would help reduce drug costs, according to HealthCare.com.

Investigators report that they have seen nearly 100% of the hormone from their tablets going straight into the liver of rats.

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.

Findings support the value of expanding this type of health care for patients with opioid use disorder.

Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are both proven to prevent more cases in older adults compared with a standard-dose vaccine in randomized controlled trials.

Final analysis of phase 2 GRIFFIN study from the Johnson & Johnson subsidiary shows the combination demonstrates stringent complete response rate for transplant-eligible patients.

Pre-specified pooled analysis from phase 3 trials demonstrates 14% reduction in CV mortality and from any cause by 10% in individuals with HF, irrespective of ejection fraction.

A new statement from the American Heart Association stresses withdrawal medications and special care teams to prevent endocarditis in these individuals.

Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.

Analysis shows that over 5 years, the percentage of women without relapse was 89% for those who had hormonal stimulation of the ovaries and 83% for those with ovarian tissue freezing.

Study results show that the risk of gaining 10% or more of body weight from the baseline fell 50% when patients were on the combination.

Georgia State University analysis supports new strategy for creating these vaccines, investigators contend.

Some function is partially restored once smokers kick the habit, results presented at the European Society of Cardiology Congress 2022 show.

Investigational targeted B-cell therapy demonstrates superior efficacy compared with teriflunomide, a commonly prescribed treatment for MS.

Analysis from the Johns Hopkins Children’s Center and University of Colorado indicates that cancellation of sports and a switch to virtual learning likely increased this risk.

Study evaluates efficacy, immunogenicity, safety of the product to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Device provides tailored relief to multiple pain areas and adds more treatment options for evolving conditions.

Analysis shows that myocarditis was the most commonly diagnosed condition associated with pediatric post-acute sequelae of SARS-CoV-2.

Additionally, approximately 70% who responded to the EnlivenHealth survey say that one-third or more of their revenue comes from individuals eligible for the government health insurance.

As more biosimilars and specialty generics enter the market next year, this could result in a shift in drug spending.

Analysis is based on previously reported data collected in March and April 2022, with the FDA granting emergency use authorization for individuals aged 6 months to 4 years on June 17.

Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.